Stock Markets June 16, 2026 04:28 PM

SOPHiA GENETICS Shares Slip After Company Announces Proposed Public Offering

Healthcare technology firm files for underwritten sale of ordinary shares; underwriters may take up to an extra 15% at the offering price

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
SOPH

SOPHiA GENETICS SA (NASDAQ:SOPH) saw its shares decline 4.7% in after-hours trading following the company's announcement of a proposed underwritten public offering of ordinary shares. The filing indicates all shares would be sold by the company, and underwriters have an option to buy up to an additional 15% of the shares at the public offering price, less the underwriting discount. The offering remains subject to market and other conditions, and TD Cowen is listed as the lead book-running manager.

SOPHiA GENETICS Shares Slip After Company Announces Proposed Public Offering
SOPH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SOPHiA GENETICS shares fell 4.7% in after-hours trading following the company’s announcement of a proposed underwritten public offering of ordinary shares.
  • The company plans to sell ordinary shares, with an option for underwriters to buy up to an additional 15% of the shares at the public offering price, less the underwriting discount - TD Cowen is the lead book-running manager.
  • The offering is conditional and subject to market and other conditions; there is no assurance as to whether or when it will be completed or what the ultimate size or terms will be. Sectors impacted include healthcare technology, clinical laboratories, hospitals, and biopharma.

SOPHiA GENETICS SA (NASDAQ:SOPH) experienced a 4.7% drop in its stock price during after-hours trading on Tuesday after the company disclosed plans for an underwritten public offering of ordinary shares.

According to the announcement, the healthcare technology company intends to sell ordinary shares in the offering, with all shares to be sold by the company itself. The filing also states that the company expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares at the public offering price, less the underwriting discount.

The company’s statement makes clear that the transaction is conditional. The offering is subject to market and other conditions, and the company noted there is no assurance as to whether or when the offering may be completed, or what the eventual size or terms will be.

TD Cowen is identified in the filing as the lead book-running manager for the offering.

SOPHiA GENETICS characterizes itself as an AI-native healthcare technology company with a focus on expanding access to data-driven medicine globally. The firm operates SOPHiA DDM, an artificial intelligence platform designed to analyze genomic and multimodal data and produce insights for hospitals, laboratories, and biopharma institutions.

The company’s public filing and the market reaction were limited to the information disclosed in the announcement. No timetable, pricing details, or further terms were provided in the company statement beyond the option for underwriters and the conditional nature of the offering.


Context and next steps

The filing outlines the basic structure of the proposed transaction and the manager engaged, but emphasizes uncertainty. The company’s note that the offering is subject to market and other conditions signals that completion, size, and terms remain open. Market participants and stakeholders in healthcare technology, clinical laboratories, hospitals, and biopharma institutions will be able to review any subsequent filings or disclosures for more detail if the company proceeds.

Risks

  • There is no assurance the offering will be completed - the filing specifies the transaction is subject to market and other conditions. This uncertainty affects capital markets activity related to the company.
  • Timing, size, and terms of the offering are unspecified and could change - stakeholders in healthcare technology and institutional investors have limited information until further disclosures are made.
  • The immediate market reaction included a 4.7% after-hours decline in the company’s shares, reflecting short-term price volatility in response to the offering announcement and potential financing developments.

More from Stock Markets

McGraw Hill Shares Tick Higher After CEO Buys Additional Stock Jun 16, 2026 Mexican Stocks Close Higher; S&P/BMV IPC Advances 0.40% Jun 16, 2026 Colombian equities slip as COLCAP falls 0.65% at Tuesday close Jun 16, 2026 Csquare Registers for NYSE IPO Under Ticker CSQR, Brookfield to Retain Voting Control Jun 16, 2026 Moscow market dips as MOEX Russia Index falls to six-month low; energy and mining weigh Jun 16, 2026